Advances in stem cell biology and immune cell engineering bring diabetes cell therapies closer to reality.

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

CryoPort Inc ( ($CYRX) ) has released its Q4 earnings. Here is a breakdown of the information CryoPort Inc presented to its investors. Cryoport, ...

Childs Cure co-founders Jainu and Shruti Jogani founded the organization to address the genetic causes of rare diseases, ...

The nonprofit’s stem cell therapy was able to completely restore the cornea in one of the 14 patients on the Phase I/II trial ...

Stem cells from a healthy eye, when transplanted into a damaged eye, safely restored corneal surfaces in 14 patients who were ...

Hearing impairment affects millions globally, with genetics playing a major role in infant hearing loss. Early screening and ...

A bill banning gene-based vaccines, like some forms of the COVID-19 vaccine, received approval from a Senate subcommittee ...

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer ...

The "AAV Vectors in Gene Therapy - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.The Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline signifies a ...

BLOOM (TAMPA) -Hormone Replacement Therapy (HRT) can be a game-changer for those struggling with hormone imbalances, but ...